临床试验/NCT01890291

NCT01890291已完成不适用

Long Term Study of 'Immuncell-LC Groups' and 'Non-treatment Groups' in Patient Undergo Curative Resection (PEIT, Radiofrequency Ablation [RFA] or Operation) for Hepatocellular Carcinoma in Korea

GC Cell Corporation5 个研究点分布在 1 个国家目标入组 162 人开始时间: 2013年6月最近更新: 2023年6月26日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: GC Cell Corporation
入组人数: 162
试验地点: 5
主要终点: To evaluate recurrence-free survival

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To observation that long term follow-up study of 'Immuncell-LC groups' and 'Non-treatment groups' in patient undergo curative resection (PEIT, RFA or Operation) for hepatocellular carcinoma in Korea

研究设计

研究类型: Observational
观察模型: Other
时间视角: Prospective

入排标准

年龄范围: 20 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Prior to the test, patient is fully explained about the purpose/ contents and characteristics of the testing medication, and the patient him(her)self, the guardian or the legal representative signed on written consent.
•Patients of participated in the(ClinicalTrials.gov Identifier:NCT00699816)clinical trial.

排除标准

•Patient who is incongruent to this clinical trial by sub-investigator's opinion.

结局指标

主要结局

To evaluate recurrence-free survival

时间窗: up to 3 years

Radiological test should be operated by dynamic CT(using 64 cut), dynamic MRI or by angiography.

次要结局

To determine the response rate to evaluate overall survival and cause specific survival and changes of Alpha feto protein (AFP) figures from baseline to the last observation date.(up to 3 years)

研究者

发起方

GC Cell Corporation

申办方类型

Industry

责任方

Sponsor

研究点 (5)

Loading locations...

相似试验

已完成

不适用

Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in KoreaHepatocellular Carcinoma

NCT06620510GC Cell Corporation230

已完成

2 期

Safety and Efficacy of "Immuncell-LC" in TACE TherapyCarcinoma, Hepatocellular

NCT02856815GC Cell Corporation76

招募中

不适用

Clinical and Immunological Outcomes of Living and Deceased Donor TransplantationTransplant Recipient (Kidney)

NCT06759831IRCCS Azienda Ospedaliero-Universitaria di Bologna1,293

进行中（未招募）

1 期

Administration of 9valent vaccine against papillomavirus in HIV-positive wome

EUCTR2018-000228-33-BECHU Saint-Pierre200

进行中（未招募）

不适用

PICAROS - Acalabrutinib RWE on 1L CLL in SpainChronic Lymphocytic Leukemia

NCT05999877AstraZeneca192